• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Pfizer (NY:PFE)

    24.63 -0.52 (-2.07%)
    Streaming Delayed Price Updated: 10:19 AM EDT, Jul 30, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Pfizer

    < Previous 1 2
    ...
    5 6 7 8 9 10 11 12 13
    ...
    99 100 Next >
    Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session. ↗
    Via Chartmill
    News headline image
    Should You Buy, Sell, or Hold Pfizer at $27? ↗
    The pharmaceutical company has been investing in its future growth, but whether its efforts will pay off is a big question mark. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Pfizer Reaches Three Settlement Agreements for VYNDAMAX
    From Pfizer Inc.
    Via Business Wire
    News headline image
    Are Wall Street Analysts Bullish on Pfizer Stock?
    Pfizer has underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects. 
    Via Barchart.com
    Topics ETFs Intellectual Property
    News headline image
    Stock Market Today, April 27: Organon Shares Surge After Sun Pharma Agrees to Acquire Company in All Cash Deal ↗
    Today, April 27, 2026, a jumbo all-cash buyout and merger-arb dynamics put Organon in focus. 
    Via The Motley Fool
    Topics Stocks
    News headline image
    Is Bristol Myers Squibb the Best Bargain in Big Pharma? ↗
    This pharma stock is cheap for a reason. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    VCIT vs. IEI Comes Down to What Job Your Bond Sleeve Is Doing ↗
    Explore how differences in bond type, risk, and income potential set these two popular ETFs apart for investors. 
    Via The Motley Fool
    Topics Bonds ETFs
    News headline image
    Is This Tech Giant the Next Potential Winner in the GLP-1 Weight Loss Boom? ↗
    The weight loss drug market may reach almost $100 billion in a few years. 
    Via The Motley Fool
    News headline image
    Is Pfizer's 6% Dividend Yield Safe? Here's What Investors Need to Know. ↗
    Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out. 
    Via The Motley Fool
    Topics Earnings
    These S&P500 stocks are the most active in today's session ↗
    Via Chartmill
    News headline image
    Unusual Put Activity Is Flagging a Smart Trade Setup in This New Quantum Computing Stock
    Quantum computing firm Infleqtion led Thursday with a 133.59 Vol/OI ratio. The Jan. 15/2027 $10 put made up 23% of volume, which was 2.8 times its 30-day average, making the trade sneaky smart. Here’s... 
    Via Barchart.com
    Topics Artificial Intelligence Initial Public Offering
    News headline image
    Wall Street Says Buy Merck Over Pfizer. The Numbers Tell a More Complicated Story.
    A tougher market puts two healthcare dividend giants in focus, as investors weigh income, stability, valuation, and long-term upside. 
    Via Barchart.com
    News headline image
    Pfizer Declares Second-Quarter 2026 Dividend
    From Pfizer Inc.
    Via Business Wire
    News headline image
    Should You Forget Pfizer and Buy This Pharma Stock Instead? ↗
    Pfizer's shares have rebounded, but is AbbVie still a better buy among pharmaceutical stocks? 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Why Merck (MRK) Shares Are Trading Lower Today
    What Happened? Shares of global pharmaceutical company Merck (NYSE:MRK) fell 3.8% in the afternoon session after the company, along with its partner Eisai, a... 
    Via StockStory
    Topics Government Intellectual Property
    News headline image
    Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
    From Pfizer Inc.
    Via Business Wire
    News headline image
    A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly ↗
    There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option. 
    Via The Motley Fool
    News headline image
    This Drug Stock Has Crushed the S&P 500 Over the Last Decade ↗
    Eli Lilly is leading the GLP-1 charge, but investors have already priced much of the good news into the stock. 
    Via The Motley Fool
    Topics Intellectual Property Stocks
    News headline image
    Where Will Pfizer Stock Be in 3 Years? ↗
    The healthcare giant has been investing heavily in its future growth. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Better Long-Term Buy: Eli Lilly or Viking Therapeutics? ↗
    One is a behemoth, the other is a minnow, but both have promising opportunities in the GLP-1 space. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    2 Value Stocks to Research Further and 1 Facing Headwinds
    Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ... 
    Via StockStory
    News headline image
    QSM Asset Management Loads Up 611,000 Mobileye Shares ↗
    Mobileye develops advanced driver assistance and autonomous driving technologies for global automotive manufacturers and suppliers. 
    Via The Motley Fool
    Topics Economy Regulatory Compliance Supply Chain
    News headline image
    A Fund Just Bet $5.7 Million on Robert Half -- Is the Staffing Sector Due for a Rebound? ↗
    Robert Half Inc. provides staffing and risk consulting solutions globally to employers across diverse industries. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    What to Look for Before Buying a Pharma Stock ↗
    Start with the drug pipeline when researching pharma stocks to own. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    QSM Asset Management Bets on Beaten-Down Manpower Group With New $5.9 Million Stake in ManpowerGroup ↗
    ManpowerGroup provides staffing and HR solutions worldwide, serving clients in 75 countries. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    J&J Shatters Estimates as Oncology and MedTech Power 2026 Outlook Higher
    Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared... 
    Via MarketMinute
    Topics Economy Intellectual Property
    News headline image
    MedTech Surge and Oncology Resilience Drive Johnson & Johnson to Q1 Earnings Beat
    In a resounding display of corporate resilience, Johnson & Johnson (NYSE:JNJ) reported first-quarter 2026 financial results that surpassed Wall Street expectations, signaling a successful navigation of... 
    Via MarketMinute
    Topics Bankruptcy Earnings Economy
    News headline image
    Earnings Preview: What to Expect From Pfizer’s Report
    Pfizer is set to report its first-quarter earnings next month, with analysts expecting profits to decline in the low double-digit range. 
    Via Barchart.com
    News headline image
    Investing $8,000 In Each of These 3 Stocks in 2026 Could Generate $1,500 in Annual Dividends ↗
    These stocks have been struggling in recent years, but they are safer investments than they appear to be at first glance. 
    Via The Motley Fool
    Topics World Trade
    News headline image
    The New J&J: A 2026 Deep Dive into the Global Healthcare Titan
    As of April 14, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different entity than it was only three years ago. Following the successful spin-off of its consumer health division, Kenvue,... 
    Via Finterra
    Topics Artificial Intelligence Death Economy
    < Previous 1 2
    ...
    5 6 7 8 9 10 11 12 13
    ...
    99 100 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.